SCHEMBL7148045

SCHEMBL7148045

COCCNc1nc(N)nc(-c2ccco2)c1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 16/20 0.61
ADORA1 P30542 16/20 0.61
POLB P06746 2/20 0.47
PKM P14618 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
ADORA3 P0DMS8 3/20 0.42
ADORA2B P29275 2/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
APAF1 O14727 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
PABPC1 P11940 1/20 0.40
PTPN7 P35236 1/20 0.40
RECQL P46063 1/20 0.40
DUSP3 P51452 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153408 0.88 ADORA2A (0.61) ADORA2AADORA1POLBPKMADORA3
SCHEMBL7403881 0.86 ADORA2A (0.59) ADORA2AADORA1POLBPKMADORA3
SCHEMBL7145305 0.85 ADORA2A (0.63) ADORA2AADORA1POLBPKMADORA3
SCHEMBL7145041 0.84 ADORA2A (0.56) ADORA2AADORA1PKMADORA3ADORA2B
SCHEMBL7146726 0.84 ADORA2A (0.64) ADORA2AADORA1POLBPKMADORA3
SCHEMBL7142633 0.83 ADORA2A (0.63) ADORA2AADORA1POLBADORA3ADORA2B
SCHEMBL7146688 0.82 ADORA2A (0.67) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL5044569 0.81 ADORA2A (0.61) ADORA2AADORA1POLBADORA3ADORA2B
SCHEMBL7150094 0.81 ADORA2A (0.46) ADORA2AADORA1POLBTRIM33ADORA3
SCHEMBL7149808 0.81 ADORA2A (0.47) ADORA2AADORA1POLBTRIM33ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885POLB 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.